New drug shows promise for calming Tourette's tics in kids
NCT ID NCT02102698
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called ecopipam in 40 children aged 7 to 17 with Tourette's syndrome. The goal was to see if it could reduce the frequency and severity of their motor and vocal tics. The drug works by blocking certain dopamine receptors in the brain. The main measure was the Yale Global Tic Severity Scale, which tracks tic symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TOURETTE'S SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
Children's Mercy Kansas City
Kansas City, Kansas, 64108, United States
-
Cincinnati Children's Hospital
Cincinnati, Ohio, 45228, United States
-
Emory University School Of Medicine
Atlanta, Georgia, 30322, United States
-
North Shore-Long Island Jewish Hosptial
Manhasset, New York, 11030, United States
-
Overlook Hospital
Summit, New Jersey, 07902, United States
-
UCLA
Los Angeles, California, 90024, United States
-
University of Chicago Medical School
Chicago, Illinois, 60637, United States
-
University of South Florida/Rothman Center for Neuropsychiatry
St. Petersburg, Florida, 33701, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Weill Cornell Medical School
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.